315 related articles for article (PubMed ID: 26166017)
1. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease.
Benson VS; Müllerová H; Vestbo J; Wedzicha JA; Patel A; Hurst JR;
Respir Med; 2015 Sep; 109(9):1147-54. PubMed ID: 26166017
[TBL] [Abstract][Full Text] [Related]
2. Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study.
Alexandropoulou K; van Vlymen J; Reid F; Poullis A; Kang JY
Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):15-21. PubMed ID: 23022985
[TBL] [Abstract][Full Text] [Related]
3. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
van Pinxteren B; Sigterman KE; Bonis P; Lau J; Numans ME
Cochrane Database Syst Rev; 2010 Nov; (11):CD002095. PubMed ID: 21069670
[TBL] [Abstract][Full Text] [Related]
4. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
van Pinxteren B; Numans ME; Bonis PA; Lau J
Cochrane Database Syst Rev; 2006 Jul; (3):CD002095. PubMed ID: 16855986
[TBL] [Abstract][Full Text] [Related]
5. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
Sigterman KE; van Pinxteren B; Bonis PA; Lau J; Numans ME
Cochrane Database Syst Rev; 2013 May; 2013(5):CD002095. PubMed ID: 23728637
[TBL] [Abstract][Full Text] [Related]
6. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
van Pinxteren B; Numans ME; Bonis PA; Lau J
Cochrane Database Syst Rev; 2000; (2):CD002095. PubMed ID: 10796857
[TBL] [Abstract][Full Text] [Related]
7. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
van Pinxteren B; Numans ME; Bonis PA; Lau J
Cochrane Database Syst Rev; 2001; (4):CD002095. PubMed ID: 11687139
[TBL] [Abstract][Full Text] [Related]
8. Gastro-oesophageal reflux disease increases the risk of intensive care unit admittance and mechanical ventilation use among patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study.
Tsai CL; Lin YH; Wang MT; Chien LN; Jeng C; Chian CF; Perng WC; Chiang CH; Chiou HY
Crit Care; 2015 Mar; 19(1):110. PubMed ID: 25887791
[TBL] [Abstract][Full Text] [Related]
9. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
van Pinxteren B; Numans ME; Bonis PA; Lau J
Cochrane Database Syst Rev; 2004 Oct; (4):CD002095. PubMed ID: 15495027
[TBL] [Abstract][Full Text] [Related]
10. Gastro-oesophageal reflux disease (GORD) in Australian general practice patients.
Miller G; Wong C; Pollack A
Aust Fam Physician; 2015 Oct; 44(10):701-4. PubMed ID: 26484482
[TBL] [Abstract][Full Text] [Related]
11. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD.
Baumeler L; Papakonstantinou E; Milenkovic B; Lacoma A; Louis R; Aerts JG; Welte T; Kostikas K; Blasi F; Boersma W; Torres A; Rohde GG; Boeck L; Rakic J; Scherr A; Tamm M; Stolz D
Respirology; 2016 Jul; 21(5):883-90. PubMed ID: 26970108
[TBL] [Abstract][Full Text] [Related]
12. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation.
Terada K; Muro S; Sato S; Ohara T; Haruna A; Marumo S; Kinose D; Ogawa E; Hoshino Y; Niimi A; Terada T; Mishima M
Thorax; 2008 Nov; 63(11):951-5. PubMed ID: 18535116
[TBL] [Abstract][Full Text] [Related]
13. Study of gastro-oesophageal reflux disease in patients with mild-to-moderate chronic obstructive pulmonary disease in India.
Kamble NL; Khan NA; Kumar N; Nayak HK; Daga MK
Respirology; 2013 Apr; 18(3):463-7. PubMed ID: 23062059
[TBL] [Abstract][Full Text] [Related]
14. Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease.
Ingebrigtsen TS; Marott JL; Vestbo J; Nordestgaard BG; Hallas J; Lange P
Respirology; 2015 Jan; 20(1):101-7. PubMed ID: 25297724
[TBL] [Abstract][Full Text] [Related]
15. Role of gastroesophageal reflux symptoms in exacerbations of COPD.
Rascon-Aguilar IE; Pamer M; Wludyka P; Cury J; Coultas D; Lambiase LR; Nahman NS; Vega KJ
Chest; 2006 Oct; 130(4):1096-101. PubMed ID: 17035443
[TBL] [Abstract][Full Text] [Related]
16. Acid suppressants for managing gastro-oesophageal reflux and gastro-oesophageal reflux disease in infants: a national survey.
Bell JC; Schneuer FJ; Harrison C; Trevena L; Hiscock H; Elshaug AG; Nassar N
Arch Dis Child; 2018 Jul; 103(7):660-664. PubMed ID: 29472195
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors use is associated with a lower risk of acute exacerbation and mortality in patients with coexistent COPD and GERD.
Su VY; Liao HF; Perng DW; Chou YC; Hsu CC; Chou CL; Chang YL; Yen JC; Chen TJ; Chou TC
Int J Chron Obstruct Pulmon Dis; 2018; 13():2907-2915. PubMed ID: 30275689
[TBL] [Abstract][Full Text] [Related]
18. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease.
Zerbib F; Belhocine K; Simon M; Capdepont M; Mion F; Bruley des Varannes S; Galmiche JP
Gut; 2012 Apr; 61(4):501-6. PubMed ID: 21997546
[TBL] [Abstract][Full Text] [Related]
19. Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: A post hoc analysis of the 2007 national health and wellness survey.
Toghanian S; Johnson DA; Stålhammar NO; Zerbib F
Clin Drug Investig; 2011 Oct; 31(10):703-15. PubMed ID: 21756007
[TBL] [Abstract][Full Text] [Related]
20. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.
Mainie I; Tutuian R; Castell DO
J Clin Gastroenterol; 2008 Jul; 42(6):676-9. PubMed ID: 18496394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
